Hearing loss
Drug research and approvals for hearing loss: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 212 studies of hearing loss are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 9 open orphan designations naming it.
- Recruiting worldwide: 212
- Trials authorized in Canada: 5
- FDA orphan approvals: 1
- EU medicines: 0
- A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With…NCT07941115 · Phase 1 / Phase 2 · Sensorion · starts Jan 1, 2027
- Audiological Rehabilitation of Children With Unilateral Hearing LossNCT07911852 · Not reported · Father Flanagan's Boys' Home · starts Jul 1, 2026
- Mi2000 TICI Follow-upNCT07902414 · Not reported · MED-EL Elektromedizinische Geräte GmbH · starts Nov 11, 2026
- Mi2000 TICI - Post-market Implantation StudyNCT07897318 · Not applicable · MED-EL Elektromedizinische Geräte GmbH · starts Nov 11, 2026
- Towards Implementation of Universal Newborn Hearing Screening in KenyaNCT07879326 · Not applicable · University of Washington · starts Sep 24, 2026
- Alpha-Tectorin, Interleukin-10 and Thiol-Disulfide Homeostasis in Children With Congenital Hearing LossNCT07860580 · Not reported · Harran University · starts Apr 20, 2026
- Auditory Intranerve Stimulation Perceptual StudyNCT07789665 · Not applicable · Hannover Medical School · starts Aug 1, 2026
- Spatial Cues, Task Demands, and Auditory Selective AttentionNCT07765186 · Not applicable · University of South Florida · starts Oct 22, 2025
- A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher…NCT07710196 · Phase 3 · Nacuity Pharmaceuticals, Inc. · starts Oct 23, 2026
Phase 3 1
- Brimapitide, c-terminal acidc-Jun N-terminal kinase 3 inhibitor
Phase 2 10
- AcetylcysteineGlutathione precursor
- DexamethasoneGlucocorticoid receptor agonist
- ZonisamideSodium channel alpha subunit blocker
- Azasetron
- PrednisoneGlucocorticoid receptor agonist
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- EbselenAntioxidant
- Mannitol
- Thiosulfuric acid
- Dextrose
Phase 1 or earlier 7
- CiprofloxacinBacterial DNA gyrase inhibitor
- OfloxacinBacterial DNA gyrase inhibitor
- AnakinraInterleukin-1 receptor antagonist
- Triamcinolone acetonideGlucocorticoid receptor agonist
- Disufenton
- Autologous cord blood
- RilonaceptInterleukin-1 beta inhibitor
How its trials ended
1,070 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 178 whose ending is known, 42% met their primary endpoint, 3% missed it and 55% stopped early.
- Completed, result not reported46944%
- Ongoing27526%
- Status unknown14814%
- Met its primary endpoint747%
- Stopped: other or unclear707%
- Stopped: enrollment or feasibility141%
- Missed its primary endpoint61%
- Stopped: lack of efficacy61%
- Stopped: sponsor or business decision4<1%
- Stopped: funding3<1%
- Stopped: safety1<1%
| Sep 25, 2026 | A trial of AAVANC80-hotof gene therapy in individuals with sensorineural hearing loss due to otoferlin gene (OTOF) mutationsAAVANC80-HOTOF | Eli Lilly | Pending |
| May 1, 2026 | Usability of the intracochlear catheter incat a pilot feasability studyDexamethasone / N-acetylcysteine / Triamcinolone | Sunnybrook Research Institute | Pending |
| Nov 29, 2024 | Usability of the intracochlear catheter incat - a pilot feasibility studyDexamethasone / Triamcinolone / Acetylcysteine | Sunnybrook Research Institute | Pending |
| Nov 15, 2024 | A phase I/II clinical trial with SENS-501 in children suffering from severe to profound hearing loss due to otoferlin (OTOF) mutationsSENS-501 | Sensorion | Pending |
| Sep 28, 2018 | A two-part, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of SENS-401 in subjects with severe or profound sudden…Azasetron (SENS-401) | Sensorion | Closed |
| Apr 23, 2026 | OtarmeniTreatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL)… | Regeneron Pharmaceuticals, Inc. | Approved |
| Jul 9, 2026 | Adeno-associated viral vector containing the hOTOF gene…Treatment of otoferlin (OTOF)-related hearing loss | Emaygene | Designated |
| Aug 6, 2024 | Dual vector gene therapy product containing recombinant…Treatment of otoferlin-mediated hearing Loss | Suzhou Otovia Therapeutics Co., Ltd. | Designated |
| Feb 29, 2024 | A novel CRISPR/Cas13X RNA base-editing therapy drugTreatment of OTOF Q829X mutation-induced hearing loss | Cholgene Therapeutics, Inc. | Designated |
| Dec 21, 2023 | Dual recombinant adeno-associated viral vectors encoding…Treatment of otoferlin-mediated hearing loss | Shanghai Refreshgene Therapeutics Co., Ltd. | Designated |
| Nov 29, 2022 | A dual vector gene therapy product containing AAV8 vectors…Treatment of otoferlin related hearing loss | Sensorion S.A. | Designated |
| May 10, 2021 | 6-fluoro-9-methyl-9H-pyrido[3,4-b]-indoleTreatment of Sudden Sensorineural Hearing Loss | AudioCure Pharma GmbH | Designated |
| Apr 12, 2021 | Melurotogene parvecTreatment of patients with otoferlin gene (OTOF)-mediated hearing loss | Eli Lilly and Company | Designated |
| Dec 12, 2019 | PioglitazoneTreatment of sudden sensorineural hearing loss | Strekin AG | Designated |
| Mar 28, 2006 | (UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor)Treatment of acute sensorineural hearing loss | Altamira Therapeutics Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA